Patent application number | Description | Published |
20080251662 | ARTICULATED SUPPORT ASSEMBLY - An articulating support assembly includes a first segment and a second segment. The first and second segments are disposed adjacent to one another. A first mating surface is defined on the first segment and a second mating surface is defined on the second segment. A tensioning assembly is operatively connected to the first and second segments such that the tensioning may be selectively operable to bias the first mating surface and the second mating surface into contact with one another thereby holding the first segment in a predetermined static orientation with respect to the second segment. | 10-16-2008 |
20100001689 | MODULAR CHARGER - A charge module adapter for a power distribution system comprising an electric device, a rechargeable battery and an adapter module, wherein the adapter module is functionally interposed between the electric device and the battery, the adapter module being in electrical communication with the electric device and the battery, wherein the adapter module is configured to selectively distribute supplied power to the electric device and the battery, and wherein the adapter module determines the operating parameters of both the electric device and the battery, and operates to selectively provide power to the electric device and the battery in dependence upon the determined operating parameters. | 01-07-2010 |
20100264738 | INTELLIGENT BATTERY SYSTEM - An intelligent battery system for powering a mobile workstation includes a mounting block having a first battery interface bracket for the releasable attachment of a first battery, a second battery interface bracket for the releasable attachment of a second battery and a third battery interface bracket for the releasable attachment of a backup battery, and a power control circuit functionally integrated with the mounting block and being capable of detecting a change in status of at least one of the first and second batteries and routing the flow of electrical power from the first, second and backup batteries in dependence thereon. | 10-21-2010 |
20100264874 | UNIVERSAL CHARGE MODULE - A universal charge module for recharging rechargeable batteries includes a housing, a connector block formed on the housing for receiving a rechargeable battery, the connector block including an attachment mechanism for releasably attaching the rechargeable battery to the housing, and a power control circuit functionally integrated with the housing, the power control circuit being capable of determining operating and charging parameters of the rechargeable battery, wherein the power control circuit controls the recharging of the rechargeable battery in dependence upon the determined operating and charging parameters. | 10-21-2010 |
20130076137 | INTELLIGENT BATTERY SYSTEM - A mobile workstation includes a first battery bracket for releasable attachment of a main battery, a second battery bracket for releasable attachment of a backup battery and a power control circuit. The power control circuit includes a first input for receiving and monitoring power from the main battery, a second input for receiving and monitoring power from the backup battery, and a DC output. The power control circuit selectively routes a first flow of electricity from the main battery to the DC output when the first flow of electricity exceeds a predetermined value, and routes a second flow of electricity from the backup battery to the DC output when the first flow of electricity falls below the predetermined value. | 03-28-2013 |
Patent application number | Description | Published |
20080305115 | Reduced-mass, long-acting dosage forms - Methods and compositions are disclosed whereby free antibody or nucleic acid co-administered with a long-acting formulation, such as a microparticle or implant, containing the antibody or nucleic acid to achieve a long duration of antibody or nucleic acid release. One result is that less of the long-acting formulation excipient or polymer is needed allowing for small-volume administrations as required, for example, for ocular, intra-dermal, orthopedic, brain and spinal delivery. In one aspect, the free antibody or nucleic acid alone has efficacy for an extended period, during which time, very little or no long-acting formulation antibody or nucleic acid is released. In one aspect, after the free antibody or nucleic acid has diminished activity, is gone, or no longer has activity, the long-acting formulation antibody or nucleic acid begins to release for a desired preprogrammed duration to provide long-acting durations. Less formulation mass is needed because the entire antibody or nucleic acid is not encapsulated or implanted with encapsulation or implant excipient or polymer. In addition, more antibody or nucleic acid can be administered to afford longer-acting formulations. | 12-11-2008 |
20090124535 | VISCOUS TERPOLYMERS AS DRUG DELIVERY PLATFORM - Disclosed are terpolymer compositions of lactide, glycolide, and caprolactone and methods of making such polymers with an initiator. Methods of using the terpolymers as a drug delivery platform are also disclosed. | 05-14-2009 |
20100003300 | INJECTABLE DELIVERY OF MICROPARTICLES AND COMPOSITIONS THEREFORE - Compositions and methods of making and using of microparticle compositions that provide faster flow or improved injectability through smaller or small-diameter needles have been developed. Notably, the microparticle compositions can be successfully delivered or administered through smaller-diameter needles than other microparticle compositions prepared from biocompatible or biodegradable polymers including, for example, poly(lactide), poly(lactide-co-glycolide), polycaprolactone, or poly-3-hydroxybutyrate. The microparticle compositions can exhibit a higher solids loading for a given needle size and/or faster flow through needles than other microparticle compositions. Further, blending or mixing the polymer of the microparticle composition with other polymer formulations can enhance the injectability of the resulting formulation. | 01-07-2010 |
20100158978 | BIOACTIVE SPRAY COATING COMPOSITIONS AND METHODS OF MAKING AND USES THEREOF - Described herein are spray coating compositions, implant devices comprising the compositions, and methods of making and using same, including point of use methods. | 06-24-2010 |
20100168807 | BIOACTIVE TERPOLYMER COMPOSITIONS AND METHODS OF MAKING AND USING SAME - Described herein are terpolymer compositions, kits comprising the compositions, implant devices comprising the compositions, and methods of making and using same, including point of use methods. | 07-01-2010 |
20100189800 | CONTINOUS DOUBLE EMULSION PROCESS FOR MAKING MICROPARTICLES - Described herein are improved methods for microparticle encapsulation. In one aspect, the disclosed methods comprise a substantially continuous double emulsion process. In a further aspects, microparticles comprising a bioactive agent therein are made by the disclosed methods. | 07-29-2010 |
20110129422 | Viscous Terpolymers as Drug Delivery Platform - Disclosed are terpolymer compositions of lactide, glycolide, and caprolactone and methods of making such polymers with an initiator. Methods of using the terpolymers as a drug delivery platform are also disclosed. | 06-02-2011 |
20110142906 | Implant Devices that Differ by Release Profile and Methods of Making and Using Same - Described herein are implant devices, kits comprising the implant devices, and methods of making and using the devices and kits. In one aspect, a plurality implant devices comprises at least two implants that exhibit a different release profile of a bioactive agent. In another aspect, an implant device comprises one or more adjoined polymer bodies, wherein at least two of the polymer bodies provide a different release profile of a bioactive agent. In another aspect, a kit comprises one or more disclosed implant devices. In another aspect, methods of delivering a bioactive agent to a subject comprise administering to the subject one or more disclosed implant devices. | 06-16-2011 |
20110204533 | Emulsion-Based Process for Preparing Microparticles and Workhead Assembly for Use with Same - The present invention relates to emulsion and double-emulsion based processes for preparing microparticles. The invention also relates to workhead assemblies for in-line flow-through mixing devices that can be used for mixing two or more fluids. The workhead assemblies can be used with the processes for preparing microparticles. | 08-25-2011 |
20110236496 | Emulsions for Microencapsulation Comprising Biodegradable Surface-Active Block Copolymers as Stabilizers - Disclosed herein are surface-active biodegradable block copolymers comprising one or more hydrophobic blocks and one or more hydrophilic blocks. The surface-active polymers are used as stabilizers in emulsions which are used in microencapsulation processes. Also disclosed are microparticles prepared from the emulsions. | 09-29-2011 |
20120004323 | IMPLANT PROCESSING METHODS FOR THERMALLY LABILE AND OTHER BIOACTIVE AGENTS AND IMPLANTS PREPARED FROM SAME - Disclosed herein are processes for preparing implants that are particularly useful for thermally labile bioactive agents but can also generally be used with any bioactive agent. The disclosed processes avoid the use of heat during processing and therefore avoid heat induced degradation of the bioactive agent. Also disclosed are implants prepared by the disclosed methods. | 01-05-2012 |
20120004324 | Process for Preparing Cyclic Esters Comprising Unsaturated Functional Groups and Polyesters Prepared From Same - Disclosed herein are process for preparing cyclic esters comprising unsaturated functional groups. Also disclosed are copolymers prepared from the cyclic esters. The copolymers can be used to form microparticles, polymer micelles, etc., which are useful in drug delivery applications. | 01-05-2012 |
Patent application number | Description | Published |
20090023651 | INHIBITORS OF HUMAN PLASMIN DERIVED FROM THE KUNITZ DOMAINS - This invention provides: novel proteins, which are homologous to the first Kunitz domain (K1) of lipoprotein-associated coagulation inhibitor (LACI), and which are capable of inhibiting plasmin; uses of such novel proteins in therapeutic, diagnostic, and clinical methods; and polynucleotides that encode such novel proteins. | 01-22-2009 |
20090036365 | INHIBITORS OF HUMAN PLASMIN DERIVED FROM THE KUNITZ DOMAINS - This invention provides: novel proteins, which are homologous to the first Kunitz domain (K1) of lipoprotein-associated coagulation inhibitor (LACI), and which are capable of inhibiting plasmin; uses of such novel proteins in therapeutic, diagnostic, and clinical methods; and polynucleotides that encode such novel proteins. | 02-05-2009 |
20090036366 | INHIBITORS OF HUMAN PLASMIN DERIVED FROM THE KUNITZ DOMAINS - This invention provides: novel proteins, which are homologous to the first Kunitz domain (K1) of lipoprotein-associated coagulation inhibitor (LACI), and which are capable of inhibiting plasmin; uses of such novel proteins in therapeutic, diagnostic, and clinical methods; and polynucleotides that encode such novel proteins. | 02-05-2009 |
20090234101 | DIRECTED EVOLUTION OF NOVEL BINDING PROTEINS - In order to obtain a novel binding protein against a chosen target, DNA molecules, each encoding a protein comprising one of a family of similar potential binding domains and a structural signal calling for the display of the protein on the outer surface of a chosen bacterial cell, bacterial spore or phage (genetic package) are introduced into a genetic package. The protein is expressed and the potential binding domain is displayed on the outer surface of the package. The cells or viruses bearing the binding domains which recognize the target molecule are isolated and amplified. The successful binding domains are then characterized. One or more of these successful binding domains is used as a model for the design of a new family of potential binding domains, and the process is repeated until a novel binding domain having a desired affinity for the target molecule is obtained. In one embodiment, the first family of potential binding domains is related to bovine pancreatic trypsin inhibitor, the genetic package is M13 phage, and the protein includes the outer surface transport signal of the M13 gene III protein. | 09-17-2009 |
20110136746 | Kallikrein-Binding "Kunitz Domain" Proteins and Analogues Thereof - This invention provides: novel protein homologous of a Kunitz domain, which are capable of binding kallikrein; polynucleotides that encode such novel proteins; and vectors and transformed host cells containing these polynucleotides. | 06-09-2011 |
20120328517 | KALLIKREIN-BINDING "KUNITZ DOMAIN" PROTEINS AND ANALOGUES THEREOF - This invention provides: novel protein homologous of a Kunitz domain, which are capable of binding kallikrein; polynucleotides that encode such novel proteins; and vectors and transformed host cells containing these polynucleotides. | 12-27-2012 |